The core structural differentiation of CD-series DAC-conjugated CJC-1295 versus unmodified CND-series CJC-1295 lies in the covalently bound lipophilic DAC carrier domain, engineered to drive reversible serum albumin binding and extended circulatory persistence:
- 29-amino-acid modified GRF(1-29) GHRH analog peptide backbone with targeted amino acid substitutions conferring DPP-4 enzymatic resistance, eliminating rapid native GHRH degradation.
- C-terminal cysteine residue forms permanent disulfide covalent linkage to the lipophilic DAC (Drug Affinity Complex) lipid carrier moiety, enabling non-covalent albumin binding in mammalian plasma.
- Albumin sequestration extends measurable systemic half-life from ~30 minutes (non-DAC CJC-1295) to approximately 7–10 days in rodent and primate preclinical models, supporting once-weekly long-duration GH-axis chronic exposure research.
- Retains full selective GHRH receptor agonism at pituitary somatotroph cells, driving amplified pulsatile growth hormone and downstream IGF-1 secretion without off-target endocrine pathway stimulation.
| Property | Value |
|---|---|
| Full Name | CJC-1295 with DAC, Lipid-Conjugated Modified GRF(1-29) GHRH Analog |
| Parent peptide CAS | 863288-34-0 |
| DAC-conjugated molecular weight | ~3367 g/mol |
| Peptide backbone length | 29 amino acids modified GHRH analog |
| Compound class | Long-acting albumin-binding GHRH growth hormone releasing hormone agonist |
| Primary molecular target | Pituitary somatotroph GHRH receptor (GH/IGF-1 secretion) |
| Circulatory half-life | 7–10 days in mammalian plasma (vs. 30min non-DAC CJC-1295) |
| Physical form | White crystalline lyophilised powder |
| Solubility | Sterile bacteriostatic water, dilute acetic acid, neutral PBS pH7.2 |
| Purity standard | ≥99% HPLC peptide content + full DAC conjugation per batch COA |
| Standard CD-series stock sizes | CD2 (2mg), CD5 (5mg), CD10 (10mg) |
CJC-1295 DAC’s extended growth hormone secretagogue activity is documented across dozens of peer-reviewed chronic endocrine, body composition and IGF-1 metabolism laboratory publications, focused on long-term weekly-dosing preclinical cohort models unavailable to short-acting unmodified GHRH analogs.
Original CJC-1295 DAC preclinical research characterized the lipid carrier albumin-binding pharmacokinetic profile, directly comparing weekly DAC-conjugated dosing versus daily non-DAC CJC-1295 administration in primate endocrine cohorts. Investigators reported sustained elevated pulsatile GH and IGF-1 concentrations over 7-day intervals following single injection, establishing the peptide as the standard reference compound for chronic once-weekly GH-axis modulation laboratory research.
CJC-1295 DAC is universally paired with Ipamorelin for dual GHRH/GHSR combinatorial growth hormone research, amplifying total pulsatile GH secretion magnitude in body composition and lean mass preclinical models. Zypep Peptides supplies CD-series DAC-conjugated vials alongside IP10 Ipamorelin standalone vials for dual agonist experimental design.
Zypep Peptides manufactures factory-direct bulk CD-series CJC-1295 DAC lyophilized powder for university endocrinology labs, sports metabolism CROs and global peptide distributors. Submit long-duration endocrine cohort research bulk inquiries via the website online chat dialog to access tiered bulk pricing, full DAC-conjugation batch COA and refrigerated worldwide shipping quotations. All CD-series products labeled FOR LABORATORY ENDOCRINE RESEARCH ONLY, not formulated for human therapeutic administration.
Reviews
There are no reviews yet.